Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 28, 2010
ALSERES PHARMACEUTICALS, INC.
Delaware | 0-6533 | 87-0277826 | ||
(State or Other Juris- | (Commission | (IRS Employer | ||
diction of Incorporation | File Number) | Identification No.) |
239 South Street, Hopkinton, Massachusetts | 01748 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (508) 497-2360
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions ( see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Table of Contents
Item 1.01. Entry into Material Definitive Agreements.
On December 28, 2010 the Company purchased from Robert L. Gipson (an affiliate of the Company) a
total of 270,000 shares of the Companys common stock held by Mr. Gipson at $0.03 per share or a
total of $8,125. The closing price for the Companys stock on December 28 was $0.15 per share.
The price per share paid by the Company to Mr. Gipson represented an 80% discount to the market
p[rice for the shares.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Alseres Pharmaceuticals, Inc. |
||||
Date: January 3, 2011 | By: | /s/ Kenneth L. Rice, Jr. | ||
Kenneth L. Rice, Jr. | ||||
Executive Vice President, Finance and Administration and Chief Financial Officer | ||||
-3-